Summary
Bristol-Myers Squibb Company (BMY) announced the consummation of the sale of its UPSA consumer health business to Taisho Pharmaceutical Holdings Co., Ltd. on July 1, 2019. This transaction, previously reported in December 2018, is expected to have a dilutive impact of approximately ($0.04) on BMY's 2019 earnings. The company has entered into related transaction agreements with Taisho, including a transitional services agreement, to facilitate the transfer. This divestiture signifies a strategic move by Bristol-Myers Squibb, likely aimed at sharpening its focus on its core biopharmaceutical operations, particularly in oncology and immunology, following its major acquisition of Celgene. Investors should monitor the impact of this sale on the company's future revenue streams and operational efficiencies. While the immediate earnings impact is projected to be modest, the long-term strategic benefits of streamlining the business portfolio are a key consideration.
Key Highlights
- 1Bristol-Myers Squibb has successfully completed the sale of its UPSA consumer health business to Taisho Pharmaceutical Holdings.
- 2The transaction closed on June 30, 2019.
- 3The sale is estimated to be dilutive to 2019 earnings by approximately ($0.04) per share.
- 4A transitional services agreement has been entered into with Taisho.
- 5This divestiture likely represents a strategic refocusing of Bristol-Myers Squibb's business.
- 6The press release announcing the consummation is attached as Exhibit 99.1.